This new study synthesized data from 5 clinical trials at the University of California, San Francisco, to evaluate the utility of minimal residual disease (MRD) and serum-free light chain (SFLC) levels in predicting progression-free survival among patients with multiple myeloma (MM) receiving chimeric antigen receptor T-cell therapies.
Metastatic renal cell carcinoma (mRCC) has seen increased treatment options in recent years, including immunotherapy (IO) combinations paired with tyrosine kinase inhibitors (TKI). A meta-analysis of phase 3 trials aimed to compare and rank available first-line treatments.
Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered dose inhaler containing hydrofluorocarbon propellant.
To date, the relative efficacy of the 3 treatments—minoxidil and 5α reductase inhibitors (5-ARIs) finasteride and dutasteride—has remained largely unknown.
Researchers sought to discover if a study specific to China would show similar patterns in health-related quality of life (HRQOL) between male and female patients with Parkinson disease (PD).
Coupled with these interventions for treating spinal muscular atrophy (SMA) is an emphasis on diagnosing the disease as early as possible to ensure optimal clinical outcomes for patients.
A recent analysis found a strong negative correlation between plasma THC levels and intraocular pressure in healthy adults after smoking cannabis.
New data from the CDC’s latest Morbidity and Mortality Weekly Report highlight disparities of HIV diagnoses among Black adults in the United States.
However, the differences did not translate into an increased or decreased death rate among the cohort.
Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, shares his thoughts on long COVID-19 among those with type 2 diabetes and the rise of new-onset cases of type 1 diabetes throughout the pandemic.
A range of new non-serum biomarkers have been identified in recent years, but the authors of a new review urge caution until those markers are further validated.
Ted Mikuls, MD, MSPH, Stokes-Shackleford professor of rheumatology, vice chair for research, internal medicine at the University of Nebraska, explains how lower extremity amputation among US veterans with gout was independent of body mass index (BMI) and other risk factors.
The national coverage determination will help detect early non-small cell lung cancer, CMS said.
Individuals in Taiwan who suffer from migraine were at an increased risk of developing neovascular age-related macular degeneration.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
CDC releases a draft of updated opioid prescribing rules; abortions in Texas drop 60% in first month of new law as patients travel out of state; COVID-19 infections can kill an unvaccinated mother's placenta.
The model identified risk factors after 6 months of treatment for the purposes of predicting overall survival and identifying which patients could benefit from a shift in treatment.
Physician and patient resistance to switching from an innovator or reference product to a biosimilar—or from one biosimilar to another—constitutes one of the major barriers to biosimilar adoption, despite the cost savings that can be achieved.
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the inflammatory mechanisms of atopic dermatitis and risk of comorbidities in affected patients.
Diagnosis delays in eosinophilic esophagitis (EoE) are common, and Colette Romero's son had symptoms soon after birth but was not diagnosed until age 3.
Adding risk factors specific to patients with chronic kidney disease (CKD) to risk prediction models for cardiovascular disease (CVD) could improve risk prediction capabilities for a population of patients often subject to invasive diagnostic procedures, investigators concluded.
Kenneth Cohen, MD, FACP, executive director of clinical research at UnitedHealth Group Research and Development and senior national medical director at OptumCare, discusses evidence-based education and other tools to address low-value care.
Megan Olsen, MPH, principal at Avalere, explains how payers are attempting to get around cost concerns associated with expensive cell and gene therapies.
This new analysis of more than 11 million veterans investigated risks of several cardiovascular diseases beyond the first 30 days after COVID-19 infection.
A new report outlines helpful strategies for pediatric patients with pulmonary arterial hypertension, although experts say more research is needed to catch up with advances in the field.
The CDC laid out a plan for mass rollout of COVID-19 vaccines for children under 5 years old, pending FDA authorization; President Biden pivots focus onto drug pricing to revive his social spending agenda; Teva opioid settlements could total $3.6 billion when all’s said and done.
Researchers reviewed advances in the management of chronic rhinosinusitis, with and without nasal polyps, from 2020 to 2021.
The researchers said they did the study with the aim of finding more information about the interaction between age and Parkinson disease (PD) in an effort to improve patient management and therapy development.
Health state utilities can be used to examine and compare the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphoma (LBCL) as more become available.
A new report from the Republic of Korea compared outcomes among women following neoadjuvant chemotherapy and mastectomy who did or did not receive radiotherapy.
